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DIFFERENTIAL PROCESSING OF PLASMA ATRIAL 
NATRIURETIC FACTOR IN CARDIOVASCULAR DISEASE 
Rainer M . Arendt, Alexander L . Gerbes, Detlef Ritter, and 
Elisabeth Stangl 
Departments of Medicine I and II, Ludwig-Maximilian-U niversity, 
Klinikum Grosshadern, 8000 Munich, Federal Republic of Germany 
The recent discovery o f the long-elusive natriuretic hormone, atrial natriuretic factor 
( A N F ) , has emphasized the importance o f the heart in blood pressure regulation and volume 
homeostasis (1). Its smallest endocrine unit is the atrial myoendocrinc cell (2) , the biological 
function of which is determined by (a) substrate uptake, (b) biosynthesis of the pre-prohor-
mone, (c) cleaving o f the signal peptide, (d) storage o f the prohormone in specific granules, 
and, upon the appropriate stimulus, (e) secretion o f the biologically active material by 
exocytosis. Under normal conditions, the posttranslational processing of the prohormone 
is l ikely to be coupled to the secretion stimulus and may occur at the secretion site. We 
have recently demonstrated the presence of the processing product ANF-28 in the circulation 
of normotensive subjects (3) . Surprisingly, it has also been shown that patients with cardiovas-
cular disease characterized by volume/pressure loading have plasma levels of A N F that 
arc considerably higher than those o f their normotensive counterparts (3 -6) . Cirrhotic patients 
showing a similarly increased extracellular volume, though mainly confined to an extravascu-
lar subcompartment, also tended to have increased plasma levels, though not significantly 
so in all studies (7 -9 ) . Head-out water immersion has recently been shown to be an important 
investigative tool in the examination o f the secretory function o f the heart (10.11). In 
addition to alterations in stimulus-response coupling, a defective posttranslational processing 
of p ro -ANF (ANF-126) or a modified target-tissue responsiveness to circulating A N F might 
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be important features in the pathophysiology of volume homeostasis. We have recently 
demonstrated that the molecular weight pattern o f plasma A N F in hypertensive patients 
differs from that seen in normotensive controls (4). Elevated plasma A N F levels in patients 
with congestive heart failure consisted predominantly of such higher molecular weight 
forms not apparent in normal subjects (12). In this study, we document plasma levels o f 
A N F in hypertensive patients, patients wi th congestive heart failure before and under convcrt-
ing-enzyme-inhibitor therapy, and in normotensive subjects and cirrhotic patients prior to 
and during head-out water immersion. A n initial structural analysis o f circulating A N F 
was achieved by use o f high-performance gel permeation chromatography of plasma extracts 
from these patients. 
METHODS 
Extraction o f plasma samples and radioimmunoassay procedures were modified from 
ref. 3. Briefly, antibody Toni I I I was used instead o f the less sensitive antibody Toni I I . 
This antibody is mid-molecule- and C-terminal-directed. Cross-reactivity with the N-termi-
nally extended cardiodilatin-88 (gift from Dr. W . G. Forssmann, Heidelberg, Federal Republic 
of Germany) was 29.7%, 35.8% to rat A N F 28, 13% to atriopeptin III, and 0.03% tu 
atriopeptin I or I i . It did not cross-react wi th a wide variety o f peptides and proteins, 
including its immunization conjugate, which is bovine thyreoglobulin. The final titer was 
1 : 120,000 and the assay sensitivity was 0.5 fmol/assay tube. The 50%-binding intercept 
o f the standard curve was 7 fmol . Synthetic standards and iodinatcd labels were from 
NovaBiochem, Läufel f ingen, Switzerland. Plasma aliquots (0 .5-3 ml) were extracted by 
adsorption to pre-rinsed Anberlite X A D - 2 adsorbent resin (particle size 0 .3-1 .0 m m , Serva, 
Heidelberg, Federal Republic o f Germany) (3). Recovery of synthetic ANF-28 was approxi-
mately 67%. Levels were not yet corrected for recovery (the results of the "International 
Collaborative Study of the Proposed International Standard for At r ia l Natriuretic Factor 
On Behalf o f The A H A / I S H / W H G ' ' pending). The intra-assay coefficient of variation 
(n = 6) was <5%>. Plasma extracts (5 ml) were subjected to high-performance gel permeation 
chromatography on a 7.5 x 600-mm TSK-125 Bio Sil column ( B i o Rad, Munich , Federal 
Republic of Germany) and eluted wi th 0.09% trifluoroacetic acid containing 0.005 m N a 2 S 0 4 
plus 0.002 m N a H 2 P 0 4 wi th 30% acetonitrile as a solvent. F low rate was 0.4 m l / m i n , and 
aliquots from column fractions were analyzed for immunoreactive A N F ( i r - A N F ) . Peripheral 
blood was drawn into prccooled syringes and immediately transferred to precooled polystyrene 
tubes containing 500 K I U / m l aprotinin and 1 mg/ml sodium E D T A . Plasma was separated 
and stored at —70C until extraction. Forty-one normotensive control subjects showing no 
evidence of cardiovascular, renal, pulmonary, or gastrointestinal disease took part in the 
study. Twenty-seven patients wi th essential hypertension were examined; at the time of 
examination, their mean blood pressure was 176 ± 4.1 over 101 ± 3.5 mm Hg. In addition, 
14 patients wi th congestive heart failure functional class N Y H A I I to IV were studied. 
Patients were hospitalized 1 week before catheterization of the heart, and all medication 
was discontinued except for diuretics and digitalis. Measurements were taken before, immedi-
ately fo l lowing , and 6 months after institution o f therapy wi th an angiotensin-converting-
enzyme inhibitor (enalapril, usually 5 mg twice dai ly) . Thirty-one patients wi th cirrhosis 
of the liver, confirmed by biochemical and histological examination, were investigated. 
Cirrhotic patients were divided into subgroups wi th and without ascites. Twelve healthy 
controls and 11 cirrhotic patients were subjected to head-out water immersion procedures. 
After void ing , subjects assumed a seated position next to the immersion tank for the first 
hour o f the experiment. Subsequently, they were immersed up to their necks, maintaining 
the same seated position in thermoncutral water (34.0 ± 0 .2°C) for 1 hr, fol lowed by an 
additional hour sitting outside the tank. Throughout the experiment, 250 ml/hr o f tap water 
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was given orally. A l l patients were on a hospital diet al lowing 150 mmol of NaCl daily. 
Experimental protocols were approved by the institutional committee on the ethics of human 
investigation. 
R E S U L T S AND DISCUSSION 
Hypertensive patients displayed a sevenfold increase in plasma A N F as compared to 
normotensive controls (62.2 ± 16.8 versus 8.8 ± 1 . 1 fmol /ml , mean ± S H M , /; < 0 .001, 
Student's /-test). A subgroup of untreated patients wi th essential hypertension had comparably 
high levels. Patients wi th congestive heart failure displayed an 18-fold increase in plasma 
A N F (158 ± 56 fmol /ml , /; < 0.001). Plasma A N F levels in cirrhotic patients (10.3 ± 
1.3 fmol /ml) were not lower than in normotensive controls. Plasma A N F levels in congestive 
heart failure patients were positively and significantly correlated to increased right atrial 
pressure and pulmonary capillary wedge pressure (/• = + 0 . 7 2 , p < 0 .01 ; and r - +0 .73 . 
p < 0 . 0 1 , respectively) and reversely related to cardiac index (r = —0.73, /; < 0.01). In 
the course o f 6 months' therapy wi th an angiotcnsin-convcrting-cnzymc inhibitor (enalapril), 
plasma A N F levels in congestive heart failure patients fe l l , in parallel wi th the hemodynamic 
improvement, to 63% of pretreatmcnt levels (from 158 ± 56 to 100 ± 50 fmol /ml . p < 
0.02, Wilcoxon paired-sample test). Head-out water immersion induced an increase in 
plasma A N F levels by 83% fol lowing 1 hr o f immersion (from 6.5 ± 0.8 to 12.0 ± 2.6 
fmol /ml , p < 0.01). This response was comparable to that seen in cirrhotic patients without 
ascites, whereas cirrhotic patients wi th ascites displayed a blunted response (a 50% increase 
as compared to a 98% increase in patients without ascites) (9). An initial structural analysis 
of plasma A N F was performed by use o f high-performance gel permeation chromatography 
in all plasma extracts. As previously reported (3) , in normotensive individuals, i r - A N F 
consisted exclusively o f authentic 3,080-dalton A N F - 2 8 , the biologically active processing 
product o f p ro -ANF (13). Such a molecular analysis in cirrhotic patients yielded a similar 
A N F 
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F I G . 1 . Molecular weight pattern of ir-ANF in the plasma of a representative patient with 
congest ive heart failure before and fol lowing institution of therapy with enalapri l . The TSK-
125 Bio Sil co lumn was calibrated with bovine serum albumin (V0), leu-enkephalin {VT), a 
series of opioid peptides, and synthetic ANF-28. Fraction aliquots were assayed for ANF-
immunoreactivi ty. 
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pattern. However, in these patients, trace amounts o f a higher-molecular-weight material 
(—13,000 daltons) was also present. This highcr-molecular-weight portion of plasma ir-
A N F did not increase in parallel to the rise in authentic ANF-28 induced by head-out 
water immersion in cirrhotic patients. This finding is in favor o f the contention that in 
these patients the stimulus-response coupling is intact and a maximal converting capacity 
of the putative pro-ANF-convert ing enzymes is not exceeded. I r - A N F in hypertensive patients 
comprised a peak cocluting wi th synthetic ANF-28 as in normotensive subjects and cirrhotics; 
in addition, a 13,000-dalton-ANF immunorcactivity and an A N F immunoreactivity eluting 
in the void volume (molecular weight > 50,000 daltons) were also present. The void-
volume A N F immunorcactivi ty most l ikely represents ANF-28 bound to carrier proteins (a 
differential recovery o f which may, in part, explain the vast differences between various 
extraction procedures and between extracted and uncxtracted assays). The elevated plasma 
A N F levels in congestive heart failure were primarily composed of such highcr-molecular-
weight forms (Fig . 1). Interestingly, therapy wi th an angiotensin-convcrting-enzyme inhibitor 
effected a reduction in total plasma A N F immunoreactivity in parallel wi th a hemodynamic 
improvement. Molecular weight analysis revealed that it was primari ly the highcr-molecular-
weight forms that were decreased rather than the authentic ANF-28 . This may indicate 
that the increased demand in these patients that cannot be met, subsequently leading to 
the release o f immature A N F forms. We conclude that a putative dysregulation o f posttransla-
tional processing o f p ro -ANF may be an important feature in the pathophysiology of cardiovas-
cular disease states. 
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